Search research articles
Contact Us
Filters
Showing results (361-370 of 785) with videos related to
Page
of 79
Sort By:
JACC. Cardiovascular Imaging
|
June 18, 2011
Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment
Markus Niemann, Sebastian Herrmann, Kai Hu, et al.
Atherosclerosis
|
August 3, 2007
Native C-reactive protein induces endothelial dysfunction in ApoE-/- mice: implications for iNOS and reactive oxygen species
Susanne B Schwedler, Peter J Kuhlencordt, P Padmapriya Ponnuswamy, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
February 17, 2009
Association of body mass index with decline in residual kidney function after initiation of dialysis
Christiane Drechsler, Renée de Mutsert, Diana C Grootendorst, et al.
Diabetes Research and Clinical Practice
|
May 22, 2024
Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial
Silvio E Inzucchi, Christoph Wanner, David Fitchett, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 27, 2014
Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis
Chantal Kopecky, Bernd Genser, Christiane Drechsler, et al.
Kidney International
|
February 12, 2015
Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease
Christiane Drechsler, Sahir Kalim, Julia B Wenger, et al.
Journal of Medical Genetics
|
June 12, 2020
Treatment switch in Fabry disease- a matter of dose?
Malte Lenders, Peter Nordbeck, Sima Canaan-Kühl, et al.
Heart (British Cardiac Society)
|
October 23, 2010
The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy
Markus Niemann, Frank Breunig, Meinrad Beer, et al.
Plos One
|
April 21, 2015
Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease
Martin Wagner, Damien R Ashby, Caroline Kurtz, et al.
Clinical Pharmacology and Therapeutics
|
December 4, 2018
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
Jonas Müntze, Daniel Gensler, Octavian Maniuc, et al.
Page
of 79
Search research articles
Search
Showing results (361-370 of 785) with videos related to
Sort By:
Page
of 79
JACC. Cardiovascular Imaging
|
June 18, 2011
Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment
Markus Niemann, Sebastian Herrmann, Kai Hu, et al.
Atherosclerosis
|
August 3, 2007
Native C-reactive protein induces endothelial dysfunction in ApoE-/- mice: implications for iNOS and reactive oxygen species
Susanne B Schwedler, Peter J Kuhlencordt, P Padmapriya Ponnuswamy, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
February 17, 2009
Association of body mass index with decline in residual kidney function after initiation of dialysis
Christiane Drechsler, Renée de Mutsert, Diana C Grootendorst, et al.
Diabetes Research and Clinical Practice
|
May 22, 2024
Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial
Silvio E Inzucchi, Christoph Wanner, David Fitchett, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 27, 2014
Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis
Chantal Kopecky, Bernd Genser, Christiane Drechsler, et al.
Kidney International
|
February 12, 2015
Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease
Christiane Drechsler, Sahir Kalim, Julia B Wenger, et al.
Journal of Medical Genetics
|
June 12, 2020
Treatment switch in Fabry disease- a matter of dose?
Malte Lenders, Peter Nordbeck, Sima Canaan-Kühl, et al.
Heart (British Cardiac Society)
|
October 23, 2010
The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy
Markus Niemann, Frank Breunig, Meinrad Beer, et al.
Plos One
|
April 21, 2015
Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease
Martin Wagner, Damien R Ashby, Caroline Kurtz, et al.
Clinical Pharmacology and Therapeutics
|
December 4, 2018
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
Jonas Müntze, Daniel Gensler, Octavian Maniuc, et al.
Page
of 79